Global Human Microbiome Sequencing Market is expected to grow at a 20.8% CAGR during the forecasting period of 2024 to 2031.
Human Microbiome Sequencing Market Size, Share & Trends Analysis Report By Product Type (Kits and Assays, Instruments, Software), By Technology, By Application, By End-User, By Region, And By Segment Forecasts, 2024 to 2031
The group of microbes that live on and in our bodies is known as the human microbiome. The human microbiota, a collective term for the billions of microorganisms that cover human tissues, includes bacteria, fungi, and viruses. The term "microbiome" refers to all of these microorganisms' genes. The human body has so many of these microorganisms that they comprise about 2-3 kg of weight. As human microbiome research develops, it is becoming clear that imbalances in gut microbiota may play a role in various non-communicable diseases, including gastrointestinal inflammation, metabolic issues, and potentially cardiovascular, pulmonary, and neurological conditions.
Numerous medical conditions, such as obesity, inflammatory bowel disease, diabetes, and others, may be treated by microbiomes. The human microbiome sequencing market is strongly influenced by the increasing prevalence of lifestyle-related diseases worldwide because therapeutics may offer an alternative approach to addressing important healthcare issues like obesity, autoimmune disorders, genomic disorders, gastrointestinal diseases, antibiotic resistance, cancer, Crohn's syndrome, and bowel syndrome. The market for human microbiome sequencing services is expanding due to the increasing number of cancer cases worldwide.
However, it is anticipated that the human microbiome sequencing industry will not expand due to a lack of knowledge and insufficient research. Additionally, barriers to establishing a causal connection between dysbiosis and diseases, a lack of favourable reimbursement scenarios and technology penetration in developing economies, and an inadequate infrastructure in low- and middle-income nations are all anticipated to pose challenges to the market during the forecast period.
The human microbiome sequencing market is segmented on the basis of product type, technology, application, and end-user. Based on product type, the market is differentiated into kits and assays, instruments, and software. Based on technology, the market is segmented into next-generation sequencing (Sequencing by Synthesis, Sequencing by Ligation and Other Next-Generation Sequencing Technologies), traditional sequencing technologies (Pyrosequencing and Sanger Sequencing) and other sequencing technology. Based on application, the market is differentiated into disease diagnosis (Gastrointestinal Diseases, Metabolic Diseases, Oncology, Infectious Diseases, Neurological Diseases and Other Diseases), drug discovery, consumer wellness, omics analysis (Genome Analysis, Metabolome Analysis, Transcriptome Analysis and Other Omics Analysis) and other application. Based on end-user, the market is differentiated into research and academic institutions, pharmaceutical and biotechnology companies, and other end users.
The drug discovery category holds the largest market share in the forecast period. The significant share of this sector can be ascribed to the expansion of novel drug discovery research initiatives as well as market participants, academic institutions, and pharmaceutical firms' drug development partnerships. In the past twenty years, the pharmaceutical business has seen a significant transformation, including a shift toward biologics, the expiration of patents, and a remarkable reduction in the internal discovery of large-scale medications. The acceptance of outsourcing drug discovery initiatives has accelerated due to everything. The pharmaceutical industry's increasing expenditure on creating novel pharmaceuticals and clinical trial research is fuelling the expansion of the global drug discovery sector.
Next-generation sequencing (NGS) refers to the extensive DNA sequencing techniques supporting genomic research. A wide range of reputable pharmaceutical and biotechnology businesses have agreed to step up to support the global research efforts to create test kits and vaccinations in the wake of the World Health Organization's (WHO) declaration of COVID-19 as a pandemic. The widespread usage of Next- Generation Sequencing (NGS) technologies due to their high efficiency and low cost are some of the main drivers propelling the growth of the Next- Generation Sequencing (NGS), along with ongoing technological advancements in sequencers. Growing technological advances in NGS equipment and technologies are also anticipated to contribute to a sizable segment size increase in the following years.
The North American human microbiome sequencing market is expected to grow faster than average due to the increasing usage of highly advanced techniques and systems in human microbiome sequencing and technological advancements in genomic research investigations. The substantial regional market growth is primarily due to the high awareness among medical professionals about the existence of cutting-edge human microbiome sequencing services in the market. The massive number of people affected by cancer and the growing demand for microbiome sequencing services for the convenience of such diseases' diagnosis and treatment is anticipated to fuel the market's expansion in the coming years. Thus, it is well known that the rising demand for human microbiome sequencing and rising investment in the health care sector are driving the market's expansion in this area.
In addition, Asia-Pacific is predicted to experience significant growth during the forecast period due to increased government initiatives to raise awareness, a rise in medical tourism, expanding research activities in the region, rising incidences of lifestyle-related diseases and autoimmune disorders, and rising demand for high-quality healthcare in the area. Additionally, the market may expand due to the rising prevalence of illnesses that lower quality of life and the expansion of the healthcare industry.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 20.8% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Product Type, Technology, Application, End-User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Baseclear B.V., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Charles River Laboratories International Inc., Clinical Microbiomics A/S, Eurofins Scientific SE, GENEWIZ, Inc., Illumina, Inc., Novogene Corporation, OraSure Technologies, Inc., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., QIAGEN N.V., Second Genome, Inc., Thermo Fisher Scientific Inc., Viome, Inc., CosmosID, Leucine Rich Bio Pvt. Ltd., Microba, Microbiome Insights Inc., and Molzym GmbH & Co. KG.. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Human Microbiome Sequencing Market By Product Type -
Human Microbiome Sequencing Market By Technology-
Human Microbiome Sequencing Market By Application-
Human Microbiome Sequencing Market By End User-
Human Microbiome Sequencing Market By Region-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.